| Assessment Status | Rapid Review Complete |
| HTA ID | 26020 |
| Drug | Dostarlimab |
| Brand | Jemperli® |
| Indication | Dostarlimab (Jemperli®) is indicated in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. This submission focuses on a subgroup of patients with recurrent or advanced deoxyribonucleic acid (DNA) mismatch repair proficient (MMRp) or microsatellite-stable (MSS) EC who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 06/05/2026 |
| Rapid review completed | 21/05/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of dostarlimab in combination with carboplatin and paclitaxel compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here
Further information on the status of this decision may be found here